<DOC>
	<DOCNO>NCT01331967</DOCNO>
	<brief_summary>Pioglitazone use treatment diabetic patient . Thiazolidinediones increase insulin sensitivity show favorable effect blood glucose level lipid profile . The effect pioglitazone atherosclerotic inflammatory marker compare prospective manner everolimus-eluting stent implantation OCT . The purpose prospective , randomize , open-label trial compare effect pioglitazone neointima volume atherosclerosis progression type 2 diabetic patient use OCT . Moreover , change neointima characteristic could analyze along change miRNA-21 , -126 , -143 , -145 . Major adverse cardiovascular event non-fatal MI , death , stroke , TLR could compare .</brief_summary>
	<brief_title>The Effect Pioglitazone Neointima Volume Characteristics Observed Optical Coherence Tomography ( OCT )</brief_title>
	<detailed_description>People diabetes mellitus prone coronary heart disease , stroke , peripheral vascular disease , diabetes mellitus regard independent risk factor progression coronary artery disease . Several study report diabetes increase risk cardiovascular mortality men woman . With introduction drug-eluting stent ( DESs ) , angiographic rate restenosis later month reduce dramatically several study . However , even DESs , diabetic patient show increased rate restenosis late loss index compare nondiabetic patient . Diabetes consider predictor poor prognosis percutaneous coronary intervention drug-eluting stent . Long-term clinical angiographic outcome percutaneous coronary intervention ( PCI ) drug-metal stent ( DESs ) demonstrate worse diabetic patient compare nondiabetic patient . In era DESs , study demonstrate clinical angiographic outcome diabetic patient DES implantation use optical coherence tomography ( OCT ) . Various microRNAs miRNA-21 , -126 , -143 , -145 involve restenosis atherosclerosis progression ( Figure 1 ) . Changes miRNAs baseline 9 month randomization never study , effect pioglitazone correlation change various miRNAs could utilize clinical practice . Comparison pioglitazone placebo 9 month follow-up neointima volume neointima characteristic optical coherence tomography ( OCT ) conduct .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Age : 18 year Gender eligible study : Diabetic patient either previously diagnose newly find diabetes . Fasting blood glucose ≥ 126 mg/dl PP2 blood glucose ≥ 200 mg/dl newly find diabetes . Patients significant coronary artery disease ( diameter stenosis &gt; 70 % ) require stent implantation . Patients informed consent . Diabetic patient use thiazolidinediones ACE inhibitor ARB allow study period Previous history PCI bypass surgery Patients contraindication treatment thiazolidinediones Pregnant lactate patient Chronic alcohol drug abuse Hepatic dysfunction Renal dysfunction Heart failure ( EF &lt; 50 % ) Expected life expectancy &lt; 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>pioglitazone</keyword>
	<keyword>optical coherence tomography</keyword>
	<keyword>microRNA</keyword>
	<keyword>neointima</keyword>
	<keyword>major adverse cardiovascular event</keyword>
</DOC>